ADMA Biologics
ADMA
34 hedge funds and large institutions have $78M invested in ADMA Biologics in 2018 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
550% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
48% more funds holding
Funds holding: 23 → 34 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital inflows, than outflows
Capital inflows: $3.36M | Capital outflows: $3.58M
52.84% less ownership
Funds ownership: 99% → 46.16% (-53%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$984K |
| 2 |
Millennium Management
New York
|
+$819K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$376K |
| 4 |
Goldman Sachs
New York
|
+$250K |
| 5 |
JP Morgan Chase
New York
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadfin Capital
New York
|
-$1.52M |
| 2 |
Morgens Waterfall Vintiadis & Co
New York
|
-$795K |
| 3 |
6CM
683 Capital Management
New York
|
-$576K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$238K |
| 5 |
Stonepine Capital Management
Bend,
Oregon
|
-$217K |
ADMA Hedge Fund Activity: Q1 2018 in Review
34 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2018, worth a combined $78M — up 43% from $54.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ADMA positions and 2 closed out — a net gain of 11 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $984K. The largest seller was Broadfin Capital, cutting an estimated $1.52M.
- 34 institutional investors held ADMA Biologics (ADMA) as of Q1 2018, up from 23 in Q4 2017.
- Funds reported $78M of ADMA Biologics stock for Q1 2018, up 43% quarter-over-quarter.
- 13 funds opened new ADMA Biologics positions in Q1 2018 and 2 closed out, a net change of +11 holders.
- The largest ADMA Biologics buyer in Q1 2018 was Vanguard Group, an estimated $984K added.
- The largest ADMA Biologics seller in Q1 2018 was Broadfin Capital, an estimated $1.52M sold.
Based on aggregated 13F filings for Q1 2018.